HER-Vaxx has successfully completed a Phase I study in breast cancer and the next stage of development will be a Phase II study in gastric cancer.

Dr Nick Ede PhD

Chief Technology Officer

Dr Ede has a record of successfully evolving research concepts to commercial products and processes. He has over 25 years experience in drug discovery and international business development gained at Chiron Corporation - now Novartis (VP Chemistry), EqiTX Ltd (COO), Mimotopes Pty Ltd (CEO), Adistem Ltd (CEO) and Consegna Ltd (CTO). He has established joint ventures and partnerships with some of the leading pharmaceutical and biotechnology companies in the world, including a global peptide supply alliance with the world's 4th largest biotechnology company Genzyme Inc, Invitrogen Inc (exclusive peptide partnership), drug discovery partnerships with GSK, J&J and Novartis, and the Broad Institute (a joint venture of Harvard and MIT) and Infinity Pharmaceuticals (NASDAQ: INFI) where his combinatorial chemistry platform technology was installed and utilised for drug discovery projects. INFI chemists made over 260,000 structurally complex compounds on his platform, which helped raise >$60M in funding spread over three chemistry deals (Amgen, J&J, Novartis).  Additionally, screening these compounds initiated an oncology program, which was subsequently partnered (Novartis) and brought in an additional $30M.  He holds a PhD from Monash University and Grad. Cert. in Innovation from Melbourne Business School, and has published over 50 scientific papers and patents.


© Imugene 2018. All rights reserved. ABN 99 009 179 551